These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35103361)

  • 1. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis.
    Fiocco Z; Kerl K; French LE; Reinholz M; Dietrich C
    Dermatol Ther; 2022 Apr; 35(4):e15351. PubMed ID: 35103361
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of baricitinib add-on therapy in atopic dermatitis patients treated with dupilumab.
    Kook HD; Hong N; Lee DH; Jung HJ; Park MY; Ahn J
    Dermatol Ther; 2022 Jul; 35(7):e15525. PubMed ID: 35441774
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report.
    He Y; Ji S; Yu Q
    Dermatol Ther; 2021 Mar; 34(2):e14878. PubMed ID: 33583117
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
    Xia D; Xiao Y; Li M; Li W
    Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
    [No Abstract]   [Full Text] [Related]  

  • 5. Atopic dermatitis and multilocular alopecia areata simultaneously treated with baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):T200-T201. PubMed ID: 37952837
    [No Abstract]   [Full Text] [Related]  

  • 6. Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):200-201. PubMed ID: 36842474
    [No Abstract]   [Full Text] [Related]  

  • 7. Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis.
    Uchiyama A; Fujiwara C; Inoue Y; Ishikawa M; Motegi SI
    J Dermatol Sci; 2022 Jun; 106(3):189-192. PubMed ID: 35459598
    [No Abstract]   [Full Text] [Related]  

  • 8. Case report: Baricitinib combined with adjuvant therapy for treatment of atopic dermatitis in a child.
    Chen JC; Lian CH
    Dermatol Ther; 2021 Mar; 34(2):e14818. PubMed ID: 33506529
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.
    De Stefano L; Bobbio-Pallavicini F; Montecucco C; Bugatti S
    Rheumatology (Oxford); 2022 Mar; 61(3):e64-e66. PubMed ID: 34647989
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience.
    Rogner D; Biedermann T; Lauffer F
    Acta Derm Venereol; 2022 Mar; 102():adv00677. PubMed ID: 35083493
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
    Dhir B; Meena SK; Sardana K; Sharath S
    Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
    Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
    De Greef A; Ghislain PD; Baeck M
    Eur J Dermatol; 2023 Dec; 33(6):707-709. PubMed ID: 38465563
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib.
    Thyssen JP; Lio P; Ball S; Pierce E; Sun L; Chen Y; Tan JKL; Augustin M
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e147-e150. PubMed ID: 34553429
    [No Abstract]   [Full Text] [Related]  

  • 16. Baricitinib for the treatment of atopic dermatitis.
    Melo A; Carrascosa JM; Torres T
    J Dermatolog Treat; 2022 Aug; 33(5):2404-2413. PubMed ID: 34379541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study.
    Uchiyama A; Fujiwara C; Inoue Y; Motegi SI
    J Dermatol; 2022 Apr; 49(4):469-471. PubMed ID: 35253254
    [No Abstract]   [Full Text] [Related]  

  • 19. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
    Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
    J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
    J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.